Dovitinib is primarily used in cancer research and development of targeted therapies. It functions as a multi-kinase inhibitor, showing activity against a range of receptor tyrosine kinases involved in tumor growth and angiogenesis, including FGFR, VEGFR, PDGFR, and FLT3. Due to its broad inhibitory profile, it has been investigated in clinical trials for various cancers such as renal cell carcinoma, breast cancer, and leukemia. Its ability to block signaling pathways that promote tumor progression makes it a valuable tool in studying resistance mechanisms and combination therapies in oncology. Dovitinib is also used in preclinical studies to understand kinase-driven tumorigenesis and to evaluate potential biomarkers for treatment response.